TELA Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)


· · Year ended December 31,
· · 2025 · · 2024 · · 2023
Cash flows from operating activities:
Net loss	$(38,831)	$(37,841)	$(46,664)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	630	632	428
Noncash interest expense	529	609	599
Noncash loss on extinguishment of debt	888	—	—
Amortization of intangible assets	380	380	380
Net changes in operating lease ROU assets and liabilities	302	(99)	(49)
Inventory excess and obsolescence charge	2,360	2,955	1,414
Stock‑based compensation expense	3,796	4,362	5,032
Income tax expense (benefit)	230	(144)	—
Gain on disposal of fixed assets	—	—	(12)
Gain on sale of product line	—	(7,580)	—
Change in operating assets and liabilities:
Accounts receivable, net	(110)	(762)	(3,058)
Inventory	(503)	(2,972)	(2,718)
Prepaid expenses and other current and long-term assets	133	227	(81)
Accounts payable	141	482	11
Accrued expenses and other current and long-term liabilities	1,760	(1,809)	4,177
Foreign currency transaction loss	76	(35)	(316)
Net cash used in operating activities	(28,219)	(41,595)	(40,857)
Cash flows from investing activities:
Purchase of property and equipment	(448)	(989)	(611)
Proceeds from the sale of product line	1,294	5,440	—
Proceeds from the sale of property and equipment	—	—	12
Net cash provided by (used in) investing activities	846	4,451	(599)
Cash flows from financing activities:
Proceeds from sale of common stock and pre-funded warrants, net	11,823	42,919	46,341
Proceeds from issuance of long-term debt and warrants	60,000	—	—
Repayment of long-term debt	(42,420)	—	—
Payment of debt financing costs	(3,554)	—	—
Proceeds from exercise of stock options	1	226	127
Payment of withholding taxes related to stock-based compensation to employees	(205)	(369)	(289)
Proceeds from issuance of common stock under the employee stock purchase plan	105	281	88
Net cash provided by financing activities	25,750	43,057	46,267
Effect of exchange rate on cash and cash equivalents	(217)	28	164
Net (decrease) increase in cash and cash equivalents and restricted cash	(1,840)	5,941	4,975
Cash and cash equivalents and restricted cash, beginning of year	52,935	46,994	42,019
Cash and cash equivalents and restricted cash, end of year	$51,095	$52,935	$46,994
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$4,716	$4,071	$4,624
Supplemental disclosures of noncash investing and financing activities:
Property and equipment in accounts payable and accrued expenses and other current liabilities	$66	$—	$119
Operating lease ROU asset exchanged for operating lease liabilities	$—	$—	$895
Offering costs in accrued expenses and other current liabilities	247	—	—
Issuance of common stock warrants in connection with credit facility	$1,413	$—	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.